Hyderabad, November 27, 2015: The US Food and Drug Administration (USFDA) has extended deadline for Dr Reddy’s laboratories Ltd to respond to its warning letters till December 7, 2015.
The Hyderabad-based Dr Reddy’s informed this to the Bombay Stock Exchange in an update on Thursday. “The company is in the process of preparing a response to the FDA’s warning letter,’’ it said.
On November 5, the US Regulator had issued a warning letter to the Hyderabad based company on its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as an Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, A P.
The time given for Dr Reddy’s to respond with corrective actions had expired originally on November 20, 2015 and it now remains to be seen how the issues are addressed as the deadline has been extended.
In the meanwhile, Dr Reddy’s scrip lost 8.22 per cent on the Bombay Stock Exchange on Thursday and is trading at Rs 3110.10 post lunch hour.-BusinessLine
Corporate Comm India(CCI Newswire)
Nagpur, May 23, 2024: The Intensivist and Critical Care team of American Oncology Institute (AOI) at…
Mumbai, May 22, 2024: The Department of Nursing at S.L. Raheja Hospital, Mahim - A…
Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…